The field of targeted cancer immunotherapy is exciting and offers promise for greatly improving treatments for many cancers. One highly promising tool is T cell bispecific antibodies (TCB), which recognise oncogene antigens (Ags) presented on the MHC-1 molecules on the surface of cancer cells, and cell surface markers from T cells. These bi-specific antibodies, therefore,… Read more »
Christian Frezza et al. at the MRC Cancer Unit, Cambridge chose to enlist the assistance of Cambridge Research Biochemicals (CRB) to raise custom polyclonal antibodies against protein succination, a post-translational modification formed by a reaction between the tricarboxylic acid cycle intermediate fumarate with protein cysteines to form S-(2-succino)cysteine (2SC). “We contacted CRB for the generation of the 2SC… Read more »
Gamma-tubulin ring complexes (γ-TuRCs) are highly conserved multi-protein complexes which localise to MTOCs (microtubule organising centres) in different parts of the cell at different times to influence microtubule array formation. Microtubule arrangement is essential to cell division and many other cell processes, and microtubule defects are associated with a variety of human pathologies. Paul Conduit… Read more »
Artilce by Dr Stephen Hoare. I met John Viles in December 2017 to discuss his work on protein misfolding and degenerative diseases. John is a structural biologist in the School of Biological and Chemical Sciences, Queen Mary University of London. He is interested in protein misfolding diseases, of which the main one is Alzheimer’s disease…. Read more »
Under a new contract, Cambridge Research Biochemicals® will support evaluation of a potential new treatment approach for Fuchs Dystrophy, a disease that typically occurs in middle age and may cause a gradual loss of vision. Cambridge Research Biochemicals (CRB), under contract to Leidos Biomedical Research, Inc., will develop reagents to evaluate eFGF-1, a compound that… Read more »
Dr. Sophie Rose and I recently met Dr. César de la Fuente when he gave the opening talk at the 8th International Meeting on Antimicrobial Peptides (IMAP 2017) in Copenhagen in August 2017. César explained how he incorporates synthetic chemical biology and computational strategies as a way of redesigning antimicrobial peptides (AMPs). He believes that… Read more »
In a collaboration with Professor Richard Grundy and Dr Farhana Haque at the Children’s Brain Tumour Research Centre (CBTRC), Layfield and co-workers employed novel mutation specific antibodies generated by Cambridge Research Biochemicals to discriminate missense (G34R and G34V) mutant histone H3 (H3.3) proteins from their wild type counterparts. The antibodies generated were shown to detect… Read more »
Antibiotic resistance is of growing concern. Antimicrobial peptides are interesting because they have the potential for treating microbial infections with less risk of resistance. Many are also involved in the innate immune system and so are also known as cationic host defence peptides. In August of this year, over 100 researchers descended on the beautiful… Read more »
Complications which arise during pregnancy are often found to be caused by a placental abnormality or malfunction, or poor placental growth and development. For these conditions, treatment is rarely available, due to the unwanted side effects of drugs and risk of birth defects in the unborn fetus. Dr Lynda K. Harris and Colleagues at the University… Read more »
Cambridge Research Biochemicals® (CRB), offering over 37 years of expertise in the custom supply of research reagents, namely peptides and antibodies for life science research and development, today signed a licence agreement with Edinburgh Innovations, the commercialisation arm of The University of Edinburgh. Under this new agreement, CRB will be permitted to label both custom… Read more »